Effects of protected sodium butyrate (PSB) in broiler diets with reduced metabolizable energy (ME) content on production performance, intestinal histomorphometry and nutrient metabolizability were evaluated in two experiments. In one experiment, 384 one-day-old male chicks with an average weight of 44 ± 0.2 g were distributed into four treatment groups in a completely randomized design with six replications of 16 birds. The treatments consisted of i) a basal diet without reduced ME or PSB (BD); ii) BD with a 100 kcal/kg reduction in ME, without PSB; iii) BD with a 100 kcal/kg reduction in ME + 105 g/t PSB; and iv) BD with a 100 kcal/kg reduction in ME + 225 g/t PSB. Performance and carcass yield were evaluated. In the second experiment, 280 one-day-old male chicks were also distributed into four treatment groups in a completely randomized design with seven replications of 10 birds to evaluate metabolizability coefficients and intestinal development. The birds that received diet 3 had the best feed conversion ratio (FCR), final weight (FW) and weight gain (WG). Inclusion of PSB (105 and 225 g/t) in reduced-ME diets increased the metabolizability of crude protein coefficient at 35 days old. Birds that received diet 3 also had greater jejunal villus height at 21 and 35 days old. It is recommended to feed 105 g/t of PSB with a 100 kcal/kg reduction in ME until broilers were 35 days old.

Maternal anxiety symptoms in the perinatal period might have long-term health effects on both the mother and the developing child. Valerian is a phytotherapeutic agent that is widely used for the treatment of anxiety. This study investigated the effects of valerian treatment in postpartum rats on maternal care, toxicity, and milk composition. Postnatal development, memory, and anxiety behavior in the offspring were also assessed. Postpartum Wistar rats received the valerian (500, 1000, or 2000 mg·kg–1·day–1) by oral gavage. Clinical and biochemical toxicity was evaluated with commercial kits. Maternal behavior was observed daily. Milk composition was analyzed by colorimetric methods. Physical and neuromotor tests were used to analyze postnatal development. Anxiolytic activity was assessed by the elevated plus maze, and memory was evaluated by the step-down inhibitory avoidance task. Maternal toxicity and care behavior were not altered by the treatment, while only the highest dose promoted a significant increase of lactose, and the doses 1000 and 2000 mg·kg–1·day–1 promoted a reduction of protein contents in milk. Postnatal development was similar in all offspring. Adult offspring did not display altered anxiety behavior, while long-term memory was impaired in the female adult offspring by maternal treatment with 1000 mg·kg–1·day–1. These results suggested that high doses of valerian had significant effects on important maternal milk components and can cause long-term alterations of offspring memory; thus, treatment with high doses of valerian is not safe for breastfeeding Wistar rat mothers.

Two experiments were conducted to evaluate the effect of including protected sodium butyrate (PSB) in the diets of laying hens of advanced age on productive performance and egg quality. In experiment 1, a total of 320 Dekalb White 61-week-old laying hens were distributed in a randomized block design to four treatments (0, 105, 210, and 300 g/ton of PSB) with eight replicates of 10 birds. The experiment was conducted over 112 days, divided into four periods of 28 days each. Productive performance and egg quality were evaluated. In experiment 2, a total of 58 000 Dekalb White 70-week-old laying hens were assigned to diets containing either 0 or 105 g/ton of PSB with two replicates of 14 500 birds. The experiment was conducted on a commercial poultry farm. Egg production and the percentages of broken eggs and dirty eggs were evaluated. The PSB levels did not influence the productive performance of laying hens. A quadratic effect was observed for eggshell thickness, percentage of eggshell and eggshell strength, reaching maxima at 193, 136 and 198 g/ton of PSB, respectively. A quadratic effect on yolk index reached a minimum at 181 g/ton of PSB. The percentages of dirty eggs and broken eggs were lower in laying hens fed 105 g/ton of PSB. In conclusion, the addition of PSB to the diets of old laying hens improved the eggshell quality and decreased the percentage of broken and dirty eggs.

The addition of protease to broiler diets may complement the action of endogenous enzymes and improve protein digestibility. Here, the authors evaluated the effect of adding protease to broiler diets that contained animal-based meal on bird performance, digestibility, and biometry of digestive tract organs. Four treatments, which contained animal- or plant-based meals with or without supplementary protease were compared, namely basal vegetable feed (BVF), BVF + protease (BFP), basal vegetable feed + animal byproduct meal (BFA), and BFA + protease. In the first experiment, 320 one-day-old Cobb 500® chicks were allocated to eight replicates with 10 birds per replicate. The experimental period was seven days, and nutrient metabolizability was evaluated. In the second experiment, 720 one-day-old Cobb 500® chicks were assigned to treatments in a similar manner, with six replicates and 30 birds per replicate, but the experimental period was 42 days. Significant differences (P <0.05) were observed between treatments for nutrient digestibility, weight gain, feed consumption, average final weight, food conversion, viability, and biometry of the pancreas. Treatments with animal-based meals had the highest digestibility. Birds fed these meals grew faster in the pre-starter phase and consumed less feed between 1 and 21 days. However, between 1 and 42 days old, broilers fed plant-based diets had better feed conversion, and the group that did not receive protease supplementation had a better liveability rate.

During thyroid tumor progression, cellular de-differentiation may occur and it is commonly accompanied by metastatic spread and loss of iodine uptake. Retinoic acid (RA) administration might increase iodine uptake in about 40% of patients, suggesting that RA could be a promising therapeutic option for radioiodine non-responsive thyroid carcinoma, although a prospective study with a long-term follow-up has not been reported. This was a clinical prospective study assessing the value of 13-cis-RA in patients with advanced thyroid carcinoma and its impact on major outcomes such as tumor regression and cancer-related death with a long-term follow-up of patients submitted to radioiodine (131I) therapy after RA administration. Sixteen patients with inoperable disease and no significant radioiodine uptake on post-therapy scan were selected. Patients were treated orally with 13-cis-RA at a dose of 1.0 to 1.5 mg·kg-1·day-1 for 5 weeks and then submitted to radioiodine therapy (150 mCi) after thyroxine withdrawal. A whole body scan was obtained 5 to 7 days after the radioactive iodine therapy. RECIST criteria were used to evaluate the response. An objective partial response rate was observed in 18.8%, a stable disease rate in 25% and a progression disease rate in 56.2%. Five patients died (62.5%) in the group classified as progression of disease. Progression-free survival rate (PFS) ranged from 72 to 12 months, with a median PFS of 26.5 months. RA may be an option for advanced de-differentiated thyroid cancer, due to the low rate of side effects.

Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the presence of either insulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) to occur. The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03% MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA content. Since goiter was already established in these animals by MMI for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MMI for different periods of time showed a progressive increase in thyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being significantly higher by the 14th day of MMI treatment, and then started to decline, reaching the lowest values by the 21st day, when a significant reduction was detected. In the liver of these animals, however, a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably involved in the insulin resistance that occurs in hypothyroidism. The increase in IRS-1 expression during goitrogenesis may represent an important event associated with the increased rate of cell mitosis promoted by TSH and indicates that insulin and IGF-I are important co-mitogenic factors in vivo, possibly acting through the activation of IRS-1.

Normal in vitro thyroid peroxidase (TPO) iodide oxidation activity was completely inhibited by a hydrolyzed TPO preparation (0.15 mg/ml) or hydrolyzed bovine serum albumin (BSA, 0.2 mg/ml). A pancreatic hydrolysate of casein (trypticase peptone, 0.1 mg/ml) and some amino acids (cysteine, tryptophan and methionine, 50 µM each) also inhibited the TPO iodide oxidation reaction completely, whereas casamino acids (0.1 mg/ml), and tyrosine, phenylalanine and histidine (50 µM each) inhibited the TPO reaction by 54% or less. A pancreatic digest of gelatin (0.1 mg/ml) or any other amino acid (50 µM) tested did not significantly decrease TPO activity. The amino acids that impair iodide oxidation also inhibit the TPO albumin iodination activity. The inhibitory amino acids contain side chains with either sulfur atoms (cysteine and methionine) or aromatic rings (tyrosine, tryptophan, histidine and phenylalanine). Among the amino acids tested, only cysteine affected the TPO guaiacol oxidation reaction, producing a transient inhibition at 25 or 50 µM. The iodide oxidation inhibitory activity of cysteine, methionine and tryptophan was reversed by increasing iodide concentrations from 12 to 18 mM, while no such effect was observed when the cofactor (H2O2) concentration was increased. The inhibitory substances might interfere with the enzyme activity by competing with its normal substrates for their binding sites, binding to the free substrates or reducing their oxidized form.